Noxopharm Ltd. (AU:NOX) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Noxopharm Limited has partnered with a seasoned Australian contract research organization to support its upcoming HERACLES clinical trial, focusing on areas such as drug safety and data management. This collaboration aims to ensure efficient trial execution and reliable data collection, marking a significant step forward for Noxopharm’s innovative cancer and inflammation treatments. The company is also progressing in selecting a Phase 1 unit to further advance the trial.
For further insights into AU:NOX stock, check out TipRanks’ Stock Analysis page.